SLC12A2 and autism: In two recent studies, a clinical trial for tuberous sclerosis complex patients with autism reported that BTN ameliorated neuropsychiatric behavioral problems but had no effect on seizure frequency or severity [86, 88], suggesting that NKCC1 antagonism with BTN is ineffective as a paradigm for reducing seizure burden.